ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 315 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,061,943 | -47.2% | 448,900 | -30.0% | 0.00% | -60.0% |
| Q2 2023 | $22,861,127 | +26.3% | 641,086 | -10.0% | 0.01% | +25.0% |
| Q1 2023 | $18,099,812 | -40.4% | 712,591 | -4.8% | 0.00% | -42.9% |
| Q4 2022 | $30,365,365 | -10.2% | 748,653 | -26.8% | 0.01% | -12.5% |
| Q3 2022 | $33,821,000 | -1.6% | 1,023,321 | +4.8% | 0.01% | 0.0% |
| Q2 2022 | $34,385,000 | -4.7% | 976,584 | +24.5% | 0.01% | 0.0% |
| Q1 2022 | $36,085,000 | -14.4% | 784,616 | +23.3% | 0.01% | 0.0% |
| Q4 2021 | $42,179,000 | -10.5% | 636,178 | -15.7% | 0.01% | -20.0% |
| Q3 2021 | $47,125,000 | -27.5% | 754,837 | -3.8% | 0.01% | -28.6% |
| Q2 2021 | $64,980,000 | +3.6% | 784,586 | -17.0% | 0.01% | -12.5% |
| Q1 2021 | $62,719,000 | -27.8% | 945,850 | -16.4% | 0.02% | -30.4% |
| Q4 2020 | $86,830,000 | +123.4% | 1,131,636 | +25.4% | 0.02% | +109.1% |
| Q3 2020 | $38,871,000 | +33.2% | 902,687 | +33.6% | 0.01% | +22.2% |
| Q2 2020 | $29,178,000 | +78.6% | 675,553 | +19.0% | 0.01% | +80.0% |
| Q1 2020 | $16,335,000 | -70.6% | 567,816 | -35.2% | 0.01% | -64.3% |
| Q4 2019 | $55,613,000 | +93.8% | 876,755 | -13.9% | 0.01% | +75.0% |
| Q3 2019 | $28,691,000 | +16.7% | 1,018,131 | +9.7% | 0.01% | +14.3% |
| Q2 2019 | $24,593,000 | +7.4% | 928,023 | -25.6% | 0.01% | 0.0% |
| Q1 2019 | $22,902,000 | +42.3% | 1,248,091 | -3.7% | 0.01% | +40.0% |
| Q4 2018 | $16,096,000 | +261.7% | 1,295,984 | +458.3% | 0.01% | +400.0% |
| Q3 2018 | $4,450,000 | +258.0% | 232,114 | +154.0% | 0.00% | – |
| Q2 2018 | $1,243,000 | -68.2% | 91,372 | -83.2% | 0.00% | -100.0% |
| Q1 2018 | $3,913,000 | +514.3% | 542,726 | +213.6% | 0.00% | – |
| Q4 2017 | $637,000 | +237.0% | 173,078 | +297.1% | 0.00% | – |
| Q3 2017 | $189,000 | -63.2% | 43,590 | -86.2% | 0.00% | – |
| Q2 2017 | $513,000 | +285.7% | 316,594 | +342.0% | 0.00% | – |
| Q1 2017 | $133,000 | -60.8% | 71,622 | -67.3% | 0.00% | – |
| Q4 2016 | $339,000 | +19.8% | 218,833 | +469.0% | 0.00% | – |
| Q3 2016 | $283,000 | +62.6% | 38,458 | +17.8% | 0.00% | – |
| Q2 2016 | $174,000 | – | 32,640 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |